Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sunshine Biopharma (SBFM) Total Current Liabilities (2016 - 2025)

Sunshine Biopharma's Total Current Liabilities history spans 11 years, with the latest figure at $6.4 million for Q4 2025.

  • For Q4 2025, Total Current Liabilities rose 2.04% year-over-year to $6.4 million; the TTM value through Dec 2025 reached $6.4 million, up 2.04%, while the annual FY2025 figure was $6.4 million, 2.04% up from the prior year.
  • Total Current Liabilities reached $6.4 million in Q4 2025 per SBFM's latest filing, down from $6.7 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $6.9 million in Q4 2022 to a low of $91229.0 in Q4 2021.
  • Average Total Current Liabilities over 5 years is $3.9 million, with a median of $5.2 million recorded in 2023.
  • Peak YoY movement for Total Current Liabilities: crashed 91.32% in 2021, then soared 7497.38% in 2022.
  • A 5-year view of Total Current Liabilities shows it stood at $91229.0 in 2021, then skyrocketed by 7497.38% to $6.9 million in 2022, then dropped by 19.9% to $5.6 million in 2023, then rose by 13.74% to $6.3 million in 2024, then rose by 2.04% to $6.4 million in 2025.
  • Per Business Quant, the three most recent readings for SBFM's Total Current Liabilities are $6.4 million (Q4 2025), $6.7 million (Q3 2025), and $5.6 million (Q2 2025).